<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030719</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069191</org_study_id>
    <secondary_id>SIOP-EUROPE-HR-NBL-1</secondary_id>
    <secondary_id>ESIOP</secondary_id>
    <secondary_id>EU-20148</secondary_id>
    <nct_id>NCT00030719</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma</brief_title>
  <official_title>High Risk Neuroblastoma Study 1 Of Siop-Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leicester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Colony-stimulating factors such as filgrastim may increase the number of immune
      cells found in bone marrow or peripheral blood and may help a person's immune system recover
      from the side effects of chemotherapy. Combining chemotherapy with peripheral stem cell
      transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more
      tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver
      tumor-killing substances to them without harming normal cells. Combining isotretinoin and
      monoclonal antibodies may kill any remaining tumor cells following surgery. It is not yet
      known which treatment regimen is more effective in treating neuroblastoma.

      PURPOSE: This randomized phase III trial is studying how well combination chemotherapy with
      or without filgrastim before surgery, high-dose chemotherapy, and radiation therapy followed
      by isotretinoin with or without monoclonal antibody work in treating patients with
      neuroblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of myeloablative therapy with busulfan and melphalan vs
           carboplatin, etoposide, and melphalan, in terms of 3- and 5-year event-free survival
           (EFS), progression-free survival (PFS), and overall survival (OS), in patients with
           high-risk neuroblastoma.

        -  Compare the 3-year EFS in these patients treated with isotretinoin with or without
           monoclonal antibody Ch14.18 after myeloablative therapy.

        -  Determine the response at metastatic sites after induction chemotherapy in these
           patients.

        -  Determine the effect of metastatic disease response after induction chemotherapy on EFS,
           PFS, and OS in these patients.

        -  Compare the toxicity and episodes of febrile neutropenia in patients treated with
           induction chemotherapy with or without filgrastim (G-CSF).

        -  Determine the effect of elective hematopoietic support with G-CSF during induction
           chemotherapy on peripheral blood stem cell collection in these patients.

        -  Compare the acute and long-term toxic effects of the 2 myeloablative therapy regimens in
           these patients.

        -  Determine the effect of radiotherapy on pre-surgical tumor volume at the primary site on
           local control, EFS, PFS, and OS in these patients.

        -  Determine the tolerability of isotretinoin with or without monoclonal antibody Ch14.18
           after myeloablative therapy in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      disease stage (2 or 3 with MycN amplification vs 4). Patients are randomized to 1 of 8
      treatment arms:

      Arm I:

        -  Patients receive induction chemotherapy comprising vincristine IV, carboplatin IV over 1
           hour, and etoposide IV over 4 hours on days 1 and 41; vincristine IV and cisplatin IV
           over 24 hours on days 11, 31, 51, and 71; and vincristine IV on days 21 and 61 and
           cyclophosphamide IV and etoposide over 4 hours on days 21, 22, 61, and 62. Patients
           receive filgrastim (G-CSF) subcutaneously on days 3-8, 12-18, 23-28, 32-38, 43-48,
           52-58, 63-68, and 72 until peripheral blood stem cell (PBSC) collection.

        -  Patients undergo PBSC collection beginning on day 80. Patients then undergo surgery on
           day 95.

        -  Patients receive myeloablative therapy comprising oral busulfan 4 times daily on days -6
           to -3 and melphalan IV over 15 minutes on day -2. Patients undergo PBSC infusion on day
           0.

        -  Patients undergo radiotherapy in 14 fractions over 21 days.

        -  Beginning within 30 days after radiotherapy, patients receive oral isotretinoin twice
           daily on days 1-14. Treatment repeats every 28 days for 6 courses.

      Arm II:

        -  Patients receive induction chemotherapy as in arm I, but with no G-CSF. Patients then
           undergo PBSC collection and surgery as in arm I. Patients receive myeloablative therapy
           and undergo PBSC infusion as in arm I. Patients undergo radiotherapy as in arm I.

        -  Patients receive oral isotretinoin twice daily on days 1-14 and monoclonal antibody
           Ch14.18 IV over 8 hours on days 1-5. Treatment repeats every 28 days for 6 courses for
           isotretinoin and every 28 days for 5 courses for monoclonal antibody Ch14.18.

      Arm III:

        -  Patients receive induction chemotherapy and G-CSF as in arm I. Patients then undergo
           PBSC collection and surgery as in arm I. Patients receive myeloablative therapy and
           undergo PBSC infusion as in arm I. Patients undergo radiotherapy as in arm I. Patients
           receive isotretinoin as in arm I.

      Arm IV:

        -  Patients receive induction chemotherapy as in arm II. Patients then undergo PBSC
           collection and surgery as in arm I. Patients receive myeloablative therapy and undergo
           PBSC infusion as in arm I. Patients undergo radiotherapy as in arm I. Patients receive
           isotretinoin and monoclonal antibody Ch14.18 as in arm II.

      Arm V:

        -  Patients receive induction chemotherapy and G-CSF as in arm I.

        -  Patients receive myeloablative therapy comprising carboplatin IV continuously and
           etoposide IV continuously on days -7 to -4 and melphalan IV over 15 minutes on days -7
           to -5. Patients undergo PBSC infusion on day 0.

        -  Patients undergo radiotherapy as in arm I. Patients receive isotretinoin as in arm I.

      Arm VI:

        -  Patients receive induction chemotherapy as in arm II. Patients receive myeloablative
           therapy and undergo PBSC infusion as in arm V. Patients undergo radiotherapy as in arm
           I. Patients receive isotretinoin and monoclonal antibody Ch14.18 as in arm II.

      Arm VII:

        -  Patients receive induction chemotherapy and G-CSF as in arm I. Patients receive
           myeloablative therapy and undergo PBSC infusion as in arm V. Patients undergo
           radiotherapy as in arm I. Patients receive isotretinoin as in arm I.

      Arm VIII:

        -  Patients receive induction chemotherapy as in arm II. Patients receive myeloablative
           therapy and undergo PBSC infusion as in arm V. Patients undergo radiotherapy as in arm
           I. Patients receive isotretinoin and monoclonal antibody Ch14.18 as in arm II.

      Patients on all treatment arms are followed every 6 months for 3 years and then annually for
      2 years.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK

      PROJECTED ACCRUAL: Approximately 175 patients per year will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival at 3 years</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean number of febrile events during induction</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate assessed by the International Neuroblastoma Response Criteria after 4 and 8 induction chemotherapy courses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival at 5 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological factors (i.e., MycNM amplification, 1p deletion, ploidy, 17 q+, CD44, and Trk-A)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of lactic dehydrogenase, ferritin, neurone specific enolase</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary catecholamines at diagnosis</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody Ch14.18</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of neuroblastoma according to International Neuroblastoma Staging System

               -  Stage 2 or 3 with MycN amplification

               -  Stage 4

          -  Tumor material available for determination of biological prognostic factors

        PATIENT CHARACTERISTICS:

        Age:

          -  1 to 20 at diagnosis

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin less than 3 times normal

          -  ALT less than 3 times normal

        Renal:

          -  Creatinine less than 1.5 mg/mL

          -  Creatinine clearance and/or glomerular filtration rate at least 60 mL/min

        Cardiovascular:

          -  Shortening fraction at least 28% OR

          -  Ejection fraction at least 55%

          -  No clinical congestive heart failure

        Pulmonary:

          -  Chest x-ray normal

          -  Oxygen saturation normal

        Other:

          -  HIV negative

          -  No Brock grade 2 or greater

          -  No uncontrolled infections requiring IV antivirals, antibiotics, or antifungals

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No more than 1 prior chemotherapy regimen for localized unresectable disease

          -  No concurrent anthracyclines

          -  No other concurrent chemotherapy

        Endocrine:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  No other concurrent investigational therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Ladenstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Anna Kinderkrebsforschung</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Ladenstein, MD</last_name>
      <phone>43-1-404-700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Laureys, MD, PhD</last_name>
      <phone>32-9-240-21-11</phone>
      <email>Genevieve.Laureys@UGent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital - Aarhus Sygehus</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Schroder, MD</last_name>
      <phone>45-89-49-44-44</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D. Valteau-Couanet</last_name>
      <phone>33-1-4211-4339</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fin Breatnach, MD, FRCPE</last_name>
      <phone>353-1-409-6659</phone>
      <email>fin.breatnach@olhsc.ie</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isaac Yaniv, MD</last_name>
      <phone>972-3-925-3669</phone>
      <email>iyaniv@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Luksch, MD</last_name>
      <phone>39-02-2390-2592</phone>
      <email>luksch@institutotumori.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingebjorg Storm-Mathisen, MD</last_name>
      <phone>47-23-07-45-60</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, SA</name>
      <address>
        <city>Lisbon</city>
        <zip>1099-023 Codex</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Forjaz De Lacerda, MD, FAAP</last_name>
      <phone>351-21-726-0429</phone>
      <email>hdiap@ipolisboa.min-saude.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Castel</last_name>
      <phone>34-96-386-2700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>S-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Kogner, MD, PhD</last_name>
      <phone>46-85-177-3534</phone>
      <email>per.kogner@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maja B. Popovic, MD</last_name>
      <phone>41-21-314-3567</phone>
      <email>maja.beck-popovic@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin W. English, MD</last_name>
      <phone>44-121-333-8412</phone>
      <email>martin.english@bch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health at University of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Kearns, MD</last_name>
      <phone>44-117-342-8260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amos Burke, MD</last_name>
      <phone>44-1223-348-151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Glaser, MD</last_name>
      <phone>44-113-206-4984</phone>
      <email>adam.glaser@leedsth.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Visser, MD</last_name>
      <phone>44-116-258-5309</phone>
      <email>johannes.visser@uhl-tr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather P. McDowell, MD</last_name>
      <phone>44-151-293-3679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Middlesex Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1T 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ananth Shankar, MD</last_name>
      <phone>44-20-7380-9300 ext. 9950</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penelope Brock, MD, PhD</last_name>
      <phone>44-20-7829-7924</phone>
      <email>Brockp@gosh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Brennan, MD</last_name>
      <phone>44-161-922-2227</phone>
      <email>bernadette.brennan@cmmc.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliet Hale, MD</last_name>
      <phone>44-191-282-4101</phone>
      <email>j.p.hale@ncl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hewitt, MD, BSc, FRCP, FRCPCH</last_name>
      <phone>44-115-924-9924 ext. 43394</phone>
      <email>martin.hewitt@nuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Wheeler, MD</last_name>
      <phone>44-186-522-1066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary P. Gerrard, MBChB, FRCP, FRCPCH</last_name>
      <phone>44-114-271-7366</phone>
      <email>mary.gerrard@sch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice A. Kohler, MD, FRCP</last_name>
      <phone>44-23-8079-6942</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Taj, MD</last_name>
      <phone>44-20-8642-6011 ext. 1307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony McCarthy, MD</last_name>
      <phone>44-289-063-3631</phone>
      <email>anthonymcarthy@royalhospital.n.i.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Neefjes</last_name>
      <phone>44-1224-550-217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Hamish Wallace, MD</last_name>
      <phone>44-131-536-0426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milind D. Ronghe, MD</last_name>
      <phone>44-141-201-9309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Traunecker, MD, PhD</last_name>
      <phone>44-29-2074-2285</phone>
      <email>heidi.traunecker@cardiffandvale.wales.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, Malis J, Papadakis V, Lacerda A, Ruud E, Kogner P, Garami M, Balwierz W, Schroeder H, Beck-Popovic M, Schreier G, Machin D, PÃ¶tschger U, Pearson A. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol. 2010 Jul 20;28(21):3516-24. doi: 10.1200/JCO.2009.27.3524. Epub 2010 Jun 21.</citation>
    <PMID>20567002</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

